Supplementary figures and methods for
The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer Supplementary figure S1 Figure S1 . Immunoblot analysis to study FLN expression in day 13 differentiated MKs from peripheral blood-derived CD34+ HSC of the GATA1 D218G patient and a healthy control. No difference in expression level was observed and no evidence for increased FLN degradation in the D218G sample could be noticed.
Figure S2. (A)
Immunoblot analysis showed no significant difference in FLN and GPIBa expression levels between platelets of the GATA1 D218G or D218Y female carriers and unrelated controls. No degradation bands related to these proteins were observed for the carrier platelets. (B) Immunoblot analysis was performed to compare NBEAL2 protein expression levels in platelets of GATA1 D218G or D218Y female carriers. No difference in NBEAL2 expression between the GATA1 D218Y female carrier and control platelets was observed while female carriers with GATA1 D218G had mildly reduced NBEAL2 levels in their platelets. We previously showed skewed X-inactivation and no mutant GATA1 mRNA in platelets from the D218Y carrier while the D218G carrier had only weak skewing of Xinactivation with the presence of the D218G mutation in platelet RNA (4) . This could mean that the D218G GATA1 mutation in her platelets resulted in slightly reduced NBEAL2 expression. However, this mild reduction in NBEAL2 seems not to have an effect on the phenotype as all GATA1 female carriers have normal platelet counts and no clinical bleeding symptoms (2,4). 
Supplementary figure S3

SUPPLEMENTARY METHODS
Patient studies
The NBEAL2 variants will be deposited in the LOVD database (under submission 
Megakaryocyte cultures, proplatelet formation and immunohistochemistry
The MK differentiation assays was performed twice with different controls. HSC were 
Immunoblot analysis
The concentration of total protein was determined by Bradford analysis and equal protein fractions (40µg) were resolved by SDS-PAGE on 5% acrylamide gels and transferred to ECL-nitro-cellulose membrane. The blots were blocked for 1h at room temperature in
Tris-buffered saline with tween (TBS-T; 0,1% Tween-20) supplemented with 5% non-fat dry milk. Blots were incubated overnight at 4°C (the dilution for all antibodies was 1:1000 in 1X
TBS-T 5% non-fat dry milk) with the following antibodies: rabbit polyclonal anti-NBEAL2 (ab151150; Abcam), rabbit monoclonal anti-NBEAL2 (ab187162; Abcam), rabbit monoclonal anti-GADPH (14C10; Cell Signaling), mouse polyclonal anti-Filamin (CP72; Calbiochem), mouse monoclonal anti-GPIBa (G27CG) (previously described 4 ), and anti-integrin b3 (sc-14009; Santa Cruz Biotechnology). Blots were washed 3 times for 10 min with 1X TBS-T.
Membranes were incubated with HRP-conjugated secondary antibodies (Dako) (dilution 1:1000 in 1X TBST 5% nonfat dry milk) for 2-3h at RT and staining was performed with ECL detection reagent (Life Technologies). Chemiluminescent blots were imaged with the ChemiDoc MP imager (Bio-Rad) and ImageJ software was used for densitometry analysis.
Luciferase reporter assays to measure NBEAL2 enhancer activity PCR was used to modify the 5 potential GATA sites and are referred to as BS-M1-2-3, (Dharmacon). This GATA1 siRNA was previously shown to be highly effective. 5 Cells were transfected with the Nucleofector II (Lonza) using the T-016 program and were collected at 24h and 48h post transfection for real time PCR and immunoblot analysis. qRT-PCR was performed to study expression of GATA1 and NBEAL2 and immunoblot analysis to detect protein expression of NBEAL2 and GADPH.
DNA binding assay
Biotynylated DNA fragments for the DNA binding assay were generated by PCR. The biotinylated PCR fragments were bound to Superparamagnetic streptavidin beads (Hyglos) and next added to NE isolated from HEK293 cells transfected with pcDNA3.1 containing GATA1 or GATA2. This binding reaction was performed with 50 µg NE and 1 µg of Poly(dI-dc) (Thermo Scientific) that were added to 1.5 µg biotinylated DNA for 3 hours at room temperature. Next beads were washed 7 times with 10xSSC (1.5 M Sodium Chloride, 0.15 M sodium citrate, pH 7) to remove unbound DNA. After addition of loading buffer, samples were loaded on a 7% SDS-PAGE. The blots were stained with anti-STAT5 (9363; Cell Signaling), anti-GATA1 (Sc-265; Santa Cruz Biotechnology) or anti-GATA2 antibody (polyclonal rabbit antibody previously described 3 ).
Glutathione S-Transferase-pull down assay with GATA1-NF
Immunoprecipitation was performed in triplicate with GATA1-NF GST-beads incubated with total protein lysates from HEK293 cells after transfection with pWPT (Trono lab, Addgene) containing the GFI1B long (NM_004188) or short (NM_001135031) isoform using jetPRIME (Polyplus). About 1 mg of HEK293 lysate was added to 500 µl RIPA buffer, with GATA1-NF GST or control GST beads for overnight incubation. After incubation and washing, the bound fraction was loaded on gel and immunoblots were performed with GFI1B antibody (sc-22795; Santa Cruz Biotechnology).
Statistical analysis
For quantitative assays, treatment groups were reported as mean ±SEM and compared using the unpaired Student t-test and one-way analysis of variance (ANOVA) test with Bonferroni's correction using Prism6 (GraphPad Software Inc.).
